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Cellular iron metabolismMany past and recent advances in the ﬁeld of iron metabolism have relied upon the use of mouse models of
disease. These models have arisen spontaneously in breeder colonies or have been engineered for global or condi-
tional ablation or overexpression of select genes. Full phenotypic characterization of these models typically
involves maintenance on iron-loaded or -deﬁcient diets, treatment with oxidative or hemolytic agents, breeding
to other mutant lines or other stresses. In this review, we focus on systemic iron biology and the contributions
that mouse model-based studies have made to the ﬁeld. We have divided the ﬁeld into three broad areas of
research: dietary iron absorption, regulation of hepcidin expression and cellular iron metabolism. For each area,
we begin with an overview of the current understanding of key molecular and cellular determinants then discuss
recent advances. Finally, we conclude with brief comments on prospects for future study. This article is part of a
Special Issue entitled: Cell Biology of Metals.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Inherited mutant or transgenic mousemodels of disease have proven
invaluable to the biomedical sciences; they offer insights into the patho-
physiology of disease that cell culture experiments or in vitro biochemical
assays typically cannot provide. The ﬁeld of ironmetabolism is no excep-
tion, where they have been actively sought out, created and studied for
more than 50 years. The ﬁrst models were spontaneous or induced ane-
mia mutants that provided for physiological study and eventually, as
the knowledge of genomes evolved, permitted phenotype-driven gene
discovery through positional cloning. Asmethods ofmanipulating animal
genomes became more advanced, prospectively engineered, gene-
targeted mutants became more common. Currently, the standard is tar-
geted global, developmental stage- and tissue-speciﬁc ablation or overex-
pression of selected genes that are often combined with nutritional or
other environmental stresses to reveal non-equilibrium phenotypes.
In this review, we have divided systemic iron biology into several
broad areas of research: dietary iron absorption, regulation of hepcidin
expression, and intracellular ironmetabolism. In each case, wewill ﬁrst
present a brief overview of the relevant molecular and cellular biology
with particular reference to the mouse and other animal models that
helped to deﬁne their relevance [1]. We will then describe more recentiology of Metals.
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l rights reserved.ﬁndings and concludewith comments on the outlook for futurework in
the ﬁeld (Fig. 1).
1.1. Dietary iron absorption
Mammals regulate systemic iron stores entirely at the level of intes-
tinal absorption; iron elimination from the body is not regulated and is
entirely dependent upon physiological and non-physiological blood
and epithelial cell loss. While dietary iron exists both as heme and
non-heme iron, the absorption of the latter is much better understood
and all animal models of aberrant dietary iron absorption appear to in-
volve non-heme iron absorption. Absorption of dietary non-heme iron
involves the liberation of elemental iron from digested food and its
maintenance in a soluble form, which is accomplished in part by gastric
acid [2]. Ferric iron (Fe3+) is then reduced to ferrous iron (Fe2+) by fer-
ric reductases present on the apical surface of duodenal enterocytes. De-
letion of one putative intestinal ferrireductase,Dcytb, has limited effects
on iron absorption, even in iron deﬁcient animals [3–5], suggesting that
Dcytb is either not essential for iron absorption or other factors such as
ascorbic acid can compensate for Dcytb deﬁciency in mice. The identiﬁ-
cation of the mutations in divalent metal transporter 1 (Dmt1, Slc11a2)
found in themicrocytic anemia (mk)mouse and the Belgrade (b) rat de-
ﬁned Dmt1 as the apical intestinal iron transporter. As Dmt1 is an
Fe2+/H+ symporter [6], the acidic microenvironment of the proximal
duodenum also promotes transmembrane iron transport. Iron trafﬁcked
across the apicalmembranemay be stored in ferritin, or trafﬁcked across
the enterocyte basolateral membrane by the Fe2+ transporter ferropor-
tin (Fpn1, Slc40a1). Fpn1 was originally cloned as the gene responsible
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The systemic iron regulatory hormone hepcidin (discussed in detail
below) regulates iron efﬂux across the basolateral membrane of the
enterocyte by binding to and causing the degradation of Fpn1. Efﬁcient
transport of iron across the basolateral membrane also requires reoxida-
tion of Fe2+ to Fe3+ by the homologous multicopper oxidases hephaes-
tin, mutated in the sex-linked anemia (sla) mouse, and ceruloplasmin
[8–10].
1.1.1. The role of duodenal acidiﬁcation in iron absorption
While the role of an acidic microenvironment in iron absorption has
been known for decades, only recently have genetic models been estab-
lished to directly assess the physiological relevance of gastric acid secre-
tion to intestinal iron absorption. For example, mice with a targeted
deletion of gastrin, which stimulates acid production by the gastric parie-
tal cell, develop a hypochromic, microcytic anemia, but only when fed an
iron-deﬁcient diet [11]. Intriguingly, in these mice, hepcidin levels do not
decrease asmarkedly as inwild-typemice on iron-deﬁcient diets. This ef-
fect may be related to the ﬁnding that parietal cells themselves express
hepcidin and that hepdicinmay also directly or indirectly regulate gastric
acid production [12]. Furthermore, based on phenotypic characterization
of the ethylnitrosourea-induced mouse mutant sublytic, it appears that
the parietal cell acid secretion is largely accomplished by the H+/K+
ATPase Atp4a [13]. These animals have increased gastric pH, decreased
serum and liver iron levels, appropriately decreased liver hepcidin levels,
and an age-dependent hypochromic, microcytic anemia that is corrected
by acidiﬁcation of drinking water. That sublytic animals show aberrant
59Fe absorption on an iron-deﬁcient, but not an iron-replete diet, further
emphasizes the notion introduced by gastrin-deﬁcient animals that duo-
denal pH may only be critical in iron-limited conditions.
1.1.2. Post-translational modulation of intestinal iron transporters
Since its description as the apical intestinal iron transporter, it has
been known that Dmt1 mRNA is strongly upregulated in response to
iron deﬁciency [6]. Dmt1 mRNA stability may also be regulated by an
iron-responsive element in the 3′untranslated region [14]. In vitro studies
indicated that Dmt1 protein degradation is regulated in a ubiquitin-
dependent manner mediated by the E3 ubiquitin ligase Nedd4-2
whose activity is facilitated by the adapter proteins Ndﬁp1 and Ndﬁp2
[15]. Ndﬁp-null mice have a complex phenotype that includes an
inﬂammation-dependent microcytic anemia; on a Rag-null immunode-
ﬁcient background these animals overexpress intestinal Dmt1 and de-
velop a mild iron overload phenotype [16]. More recently it has been
reported that the enterocyte basolateral transporter Fpn1 is also regu-
lated by Nedd4-2 and Ndﬁp in a hepcidin-independent manner [17],
suggesting that the iron overload phenotype seen in immunodeﬁcient
Ndﬁp-null mice may also be related to inappropriate persistence of
Fpn1 expression. Expression of Dmt1 and Fpn1 is also dependent
upon iron regulatory proteins (Irp) 1 and 2, RNA-binding proteins that
regulate protein expression by binding to RNA motifs known as iron-
responsive elements (IREs). Mice with combined intestinal Irp1 and 2
deﬁciency exhibit aberrant intestinal villus architecture and die postna-
tally from intestinal malabsorption and dehydration [18]. At the molec-
ular level, these mice also display aberrant expression levels of known
Irp targets including Tfr1, ferritin H and L chains, Fpn1 and surprisingly
+IRE and−IRE forms of Dmt1. Increased liver hepcidin levels may re-
ﬂect decreased erythropoietic inhibition or increased inﬂammatory
stimulation of unclear etiology, given that serum or tissue iron levels
are not perturbed. Notably the increased Fpn1 protein levels in spite
of increased hepcidin levels indicate that Irp activity is essential for
Fpn1 regulation.
1.1.3. Regulation of intestinal iron absorption by ferritin
Ferritin is a multimeric protein composed of H (Fth) and L (Ftl)
chains capable of storing up to 4500 Fe3+ ions per multimer. The
early embryonic lethality of Fth deﬁciency in mice [19] prompted theinterrogation of ferritin function using a conditional deletion strategy.
Fth deletion induced in adulthood leads to decreased tissue iron stores
when fed a diet with normal iron content and severe liver damage
when fed a high-iron diet [20]. Intestine-speciﬁc deletion of the Fth
chain indicates that intestinal ferritin is essential for appropriate dietary
iron absorption [21]. These mice display increased serum and tissue
iron levels and appropriately increased hepcidin levels. The observed in-
crease in intestinal 59Fe absorption and Fpn1 expression may reﬂect in-
activation of intestinal Irp activity by increased intracellular iron levels.
1.1.4. Regulation of intestinal iron absorption by hypoxia inducible
factors
Increased iron absorption is one of the metabolic adaptations to
hypoxia. Hypoxia-induced transcriptional programs are mediated pri-
marily by the transcription factors Hif1 and Hif2 and regulated by the
von Hippel–Lindau factor (VHL or Vhlh) E3 ubiquitin ligase and
oxygen-dependent prolyl hydroxylases. Hif1 and Hif2 share a common
β subunit, Arnt (aryl hydrocarbon nuclear translocator), and each has a
labileα subunit that is degraded in a Vhlh- and proteasomal-dependent
manner in iron- and oxygen-replete conditions. With the use of germ-
line and tissue-speciﬁc conditional deletions of genes in this pathway,
it has been possible to dissect those changes that are a consequence of
a direct effect on intestinal epithelial cells and those that are secondary
to primary responses in other organs.
Several research groups have investigated the role of the Hif pathway
in regulating iron metabolism in intestinal cells. Mastrogiannaki et al.
characterized mice with intestinal Hif1α or Hif2α deﬁciency [22]. Only
in the latter did they observe signiﬁcant alterations in iron metabolism,
including decreased intestinal Dmt1 and Fpn1mRNA levels that were as-
sociated with decreased serum and liver iron levels, increased serum
erythropoietin and decreased hepatic hepcidin expression. Despite the
decreased mRNA levels, duodenal Fpn1 protein expression was
unchanged, likely reﬂecting equilibrium between decreased Hif2-
dependent effects on Fpn1 mRNA and decreased hepcidin-dependent
Fpn1 protein destabilization. An iron-deﬁcient diet worsened hemato-
logic parameters in intestinal Hif2α-deﬁcient mice but not wild-type
controls. Taylor et al. also found that intestinal Hif2α deﬁciency abro-
gated the increase in duodenal Fpn1 protein observed in mice placed
on an iron-deﬁcient diet [23]. Shah and colleagues, using Vhlh- and
Hif1α-deﬁcient mice, which lack Hif1 and have constitutively active
Hif2, as well as Vhlh- and Arnt-deﬁcient mice, which lack both Hif1
and HIf2 activity, reached largely similar conclusions [24]. The pivotal
role of intestinal Hif2α has been further tested by treating intestinal
Hif2α-deﬁcient mice with the hemolytic agent phenylhydrazine [25].
Results of these studies indicate that Hif2α is essential for the increased
intestinal Dmt1 mRNA and protein levels and increased serum iron
levels but not the increased renal erythropoietin and intestinal Fpn1
levels seen in acute hemolysis. Also consistent with a cell-autonomous
role for Hif2α in the regulation of intestinal iron absorption is the recent
ﬁnding that enterocyte Hif2α deﬁciency attenuates tissue iron loading
in hepcidin-deﬁcient mice [26].
1.2. Regulation of hepcidin expression in hepatocytes
As described above, intestinal iron absorption, and consequently
total body iron, is strongly inﬂuenced by hepcidin, a peptide hormone
synthesized predominantly by hepatocytes in the liver that circulates
in the plasma and induces internalization and lysosomal degradation
of Fpn1 [27]. Hepcidin expression is stimulated by iron overload and
inﬂammation and inhibited by anemia and hypoxia. Given the central
role of hepcidin in modulating systemic iron stores, the regulation of
hepcidin is one of the most active areas of research within the ﬁeld of
iron biology [28].
Inmanyways, our early understanding of the regulation of hepcidin
in hepatocytesmirrored the identiﬁcation of genes responsible for auto-
somal recessive (AR) forms of the human iron overload disorders
Fig. 1. Recent advances in animal models of aberrant iron metabolism. Models of iron metabolism in the enterocyte, hepatocyte, macrophage and erythroid precursor are shown
with labels indicating those gene products for which models of deﬁciency have been recently reported. For simplicity, not all sites of gene/protein function are indicated nor are
all factors essential for iron metabolism shown. Red and green fonts indicate that a factor acts in a stimulatory or inhibitory manner respectively. For a more detailed description
of gene function, refer to text. In the gastrointestinal tract, gastrin and Atp4a stimulate gastric acidiﬁcation, thereby aiding food digestion and maintenance of Fe3+ solubility. After
reduction of Fe3+ to Fe2+, iron is transported into the enterocyte by Dmt1, the levels of which are respectively increased and decreased by activity of Hif2α and Ndﬁp1. Within the
enterocyte, ferritin stores iron and indirectly regulates the rate of gastrointestinal iron absorption, while iron regulatory proteins Irp1 and Irp2 inﬂuence levels of Dmt1 and Fpn1.
Hif2α activity leads to increased basolateral membrane levels of Fpn1, which efﬂuxes iron into plasma for oxidation and binding to Tf. In the hepatocyte, diferric Tf and Bmp6 stim-
ulate hepcidin expression via a pathway dependent upon Hfe, Tfr2, Alk2, Alk3 and Hjv. Expression levels of Hjv are increased by activity of neogenin and miR-122 and decreased by
activity of Tmprss6. Expression of hepcidin is also inﬂuenced by Hif1α, Hif2α, Vhl, Irp2 and Fbxl5. In the macrophage, senescent red blood cells are catabolized. Nramp1 mediates
iron efﬂux from phagolysosomes, while HRI is required for macrophage maturation. Fpn1 efﬂuxes reclaimed iron into the plasma for binding to Tf; Hif2α activity stimulates Fpn1
expression levels. In the erythroid precursor, Fe is obtained by receptor-mediated endocytosis of diferric Tf complexed to Tfr1, the levels of which are regulated by Stat5a/b and
Nme1/2. Iron is imported into mitochondria by mitoferrin while Fech catalyzes the incorporation of iron into heme precursors. Flvcr maintains heme at appropriate levels within
the erythroid precursor.
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to loss of function mutations in HFE, hemojuvelin (HJV), transferrin re-
ceptor 2 (TFR2) or hepcidin (HAMP) itself. In each case, the expression
of hepcidin is inappropriately low for the degree of iron stores and the
severity of the iron overload is roughly proportional to the extent of rel-
ative hepcidin deﬁciency. Cell-based assays demonstrated that there is a
network of interactions between diferric transferrin (Fe2TF), transferrinreceptor 1 (TFRC or TFR1), TFR2 and HFE in which Fe2TF competes with
HFE for binding to TFR1. In thismanner, HFE binding to TFR2 is sensitive
to the concentration of Fe2TF. HJV is a bone morphogenetic protein
(BMP) co-receptor essential for hepcidin regulation in hepatocytes
that appears to be functionally downstream of HFE and TFR2. Taken to-
gether, these data have led to the notion that loss of any of the AR HH
proteins leads to a defect in “iron sensing” by the hepatocyte and that
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Fe2TF levels, which normally serve to induce its production [28]. Not
surprisingly, soon after the description of each AR HH gene, a targeted
loss of function mutation in the mouse for each of these proteins was
shown to reproduce the HH phenotype. There are also mouse models
of AR HH established for reasons other than validation of genes identi-
ﬁed in patient studies—examples includemice deﬁcient in β2-microglo-
bulin, a factor believed to be required for HFE localization, and recently
developed mouse models which will be reviewed here. These recent
models have focused on delineating the requirements for these proteins
in ironmetabolism in a cell-type speciﬁcmanner, further characterizing
the interrelationships of the AR HH proteins, and identifying or validat-
ing other proteins involved in the pathway.
1.2.1. Hereditary hemochromatosis is a primary liver disease dependent
on the interactions of the AR HH proteins and TF
Although the predominant expression of hepcidin by the liver
would suggest that primary, and not secondary, defects in hepatocyte
hepcidin expression would underlie the pathogenesis of AR HH, the
widespread expression of HJV, HFE, and to a much lesser extent
TFR2, indicated that other tissues might contribute to hepatocellular
hepcidin dysregulation. The creation of conditionally targeted alleles
of all three proteins, however, has dispelled any of these hypotheses
and has helped elaborate the mechanisms by which they each inﬂu-
ence hepcidin gene transcription in the liver.
Several animalmodels demonstrate that HFE plays a role in hepcidin
regulation in the liver. Most directly, mice lacking Hfe only in hepato-
cytes have a hemochromatosis phenotype identical to animals lacking
global expression of the molecule [29]. Conversely, overexpression of
Hfe in a liver-speciﬁc manner is not only able to correct the hemochro-
matosis phenotype of Hfe-deﬁcient mice, but in fact leads to elevated
hepcidin expression and a microcytic, hypochromic anemia [30,31].
Similarly, adenoviral expression of Hfe in the liver of wild-type or Hfe-
deﬁcient animals is able to upregulate hepcidin expression [32].
As described above, the prevailing model of HFE function holds that
HFE acts as a sensor for the concentration of Fe2TF. Analysis ofmicewith
mutations in Tfr1 that promote the Hfe-Tfr1 interaction demonstrated
that, when Hfe is sequestered by Tfr1, animals develop iron overload
and have inappropriately low hepcidin expression. Conversely, animals
withHfemutations that abrogate the ability of Hfe to bind to Tfr1 devel-
op an iron deﬁciency related to hepcidin overexpression [30]. In con-
trast to cell culture work demonstrating that the cytoplasmic tail is
crucial for Hfe function [33], mouse models overexpressing Hfe lacking
the cytoplasmic domain exhibit upregulated hepcidin expression lead-
ing to decreased total body iron stores [31].
The role that TF plays in regulating hepatocyte hepcidin expres-
sion has also recently been investigated using the hypotransferrinemia
(hpx) mouse model of transferrin deﬁciency [34]. Due to the essential
role of TF in delivering iron for erythropoiesis, these animals suffer
from severe hypochromic, microcytic, iron deﬁciency anemia. How-
ever, perhaps paradoxically, hpx animals have massive systemic iron
overload and profound hepcidin insufﬁciency. Transfusion of hpx an-
imals with wild-type red blood cells leads to increased hepcidin
levels, suggesting that anemia and/or hypoxia suppress hepcidin ex-
pression. Furthermore, treatment of hpx mice with the chemothera-
peutic agent doxorubicin, thereby ablating erythropoiesis, and then
with TF also leads to increased hepcidin levels. This indicates that TF
can stimulate hepcidin expression independently of its role in eryth-
ropoiesis [35]. Similar transfusion experiments were also performed
in hpx animals on an Hjv-deﬁcient background. In this case, there
was a very poor hepcidin response following TF supplementation, in-
dicating that Hjv is essential for TF-dependent and -independent
hepcidin expression [36].
While the phenotype of hepcidin deﬁciency and iron overload
observed in mice with liver-speciﬁc Tfr2 deﬁciency suggests that
the regulation of hepcidin expression by Tfr2 depends upon Tfr2activity in the liver [37], the mechanism by which this regulation
occurs is uncertain. A potential functional relationship between
Hfe and Tfr2 has been explored using several different mouse
models. Mice deﬁcient in both Hfe and Tfr2 have been shown
to have more severe iron loading than animals lacking either
gene alone [38], and when normalized to iron stores, hepcidin
expression was more profoundly suppressed in animals lacking
both proteins. Moreover, induction of hepcidin by lipopolysaccha-
ride (LPS), which models inﬂammation-induced hepcidin expres-
sion, is blunted in mice deﬁcient in Hfe, Tfr2 or both proteins,
and that this effect is most pronounced in the double mutant
[39].
Germline targeted mutation of Hjv has been shown by several
investigators to result in an HH phenotype [40,41]. Interestingly,
however, HJV mRNA is most highly expressed in skeletal muscle
and only at lower levels in liver [42]. As a soluble form of HJV is
found in circulation and had been shown to modulate BMP-
mediated regulation of hepcidin expression, it has been hypothe-
sized that soluble HJV produced in muscle is potentially relevant
to hepatic hepcidin expression. However, liver- and skeletal
muscle-speciﬁc Hjv deletion models show that this clearly is not
the case. Loss of Hjv in the liver alone is sufﬁcient to cause hepatic
hepcidin deﬁciency and systemic iron overload, whereas, ablation
of Hjv in skeletal muscle has no effect on iron loading or hepcidin
expression [43,44].
1.2.2. BMP6, ALK2 and ALK3 are the BMP isoform and BMP type I receptors
most relevant to hepcidin regulation
In vitro studies had indicated that several different BMP isoforms
stimulate hepcidin production. Studies in wild type mice fed iron-rich
or -deﬁcient diets demonstrated that Bmp6 protein levels correlated
with iron levels [45], suggesting that this protein was most relevant to
regulating hepcidin in vivo. This was conﬁrmed by two research groups
who demonstrated simultaneously that global deletion of Bmp6 in mice
causes a severe HH phenotype [46,47]. Furthermore, treatment of mice
with a Bmp6-neutralizing antibody inhibits hepcidin expression and in-
creases serum iron levels, while treatment of mice with Bmp6 increases
hepcidin expression and reduces serum iron levels [46]. Although the
tissue-speciﬁc targeted deletion studies have not yet been performed,
several reports have indicated that the liver is the main source of Bmp6
[48–50]; one conﬂicting study, however, suggests that the duodenum is
the predominant site of BMP6 expression [51].
Studies in multiple animal models have demonstrated that Hfe func-
tions in BMP-mediated regulation of hepcidin expression. Liver-speciﬁc
overexpression of Hfe leads to elevated hepcidin expression due to in-
creased BMP signaling, decreased tisue iron levels and microcytic, hypo-
chromic anemia [30,31,52]. Conversely, Hfe-deﬁcient mice, although
iron overloaded, do not have elevated levels of hepatic phosphorylated
Smad 1/5/8 protein and other markers of BMP signaling [52,53]. Never-
theless Bmp6 expression is appropriately increased in the iron-loaded
livers of Hfe-deﬁcient mice, demonstrating that Hfe is not necessary for
regulation of Bmp6 by iron. Treatment of transgenicmice overexpressing
Hfe with a Bmp6-neutralizing antibody decreases hepcidin expression
and increases iron stores [54]. Conversely, treatment of Hfe-deﬁcient
mice with Bmp6 increases hepcidin expression leading to reduced
serum iron and TF saturation. Transgenic hepatic overexpression of Hfe
in Hjv-deﬁcient mice does not increase hepcidin expression or modulate
Hjv-deﬁcient iron overload [31]. In total, these studies indicate loss of Hfe
and Hjv do not impair Bmp6 production by the hepatocyte in response to
iron, but do, to a lesser and greater degree, respectively, inhibit BMPR/
SMAD-dependent signaling and hepcidin transcription in response to
Bmp6.
Although it was well established that HJV was a BMPR co-receptor
[55,56], it was not clear which of the type I or II BMPRs was required
for HJV-dependent signaling in response to Bmp6 and iron. An initial
clue came from the treatment of mice with the drug dorsomorphin,
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was found to inhibit hepcidin expression [57]. Subsequently, it was
shown that liver-speciﬁc deletions of Alk2 or Alk3 cause iron overload
in mice, but loss of Alk3 caused a more pronounced iron loading due
to more substantial downregulation of BMP signaling and hepcidin
expression [58]. Although Alk6 is also expressed in hepatocytes, loss
of this receptor does not appear to affect hepcidin expression.
1.2.3. Regulation of hepatocellular HJV expression and function by multiple
mechanisms alters hepcidin production
Commensurate with the severe, juvenile onset HH phenotype
seen in human patients with biallelic mutations in HJV, hepatocyte
hepcidin expression appears to be exquisitely tuned to the levels of
HJV protein expressed by the hepatocyte. At least three distinct
post-transcriptional mechanisms of modulating HJV expression have
been described.
Beutler and colleagues identiﬁed themaskmouse in a chemicalmuta-
genesis screen for mouse phenotypic abnormalities. Homozygous mask
mice have microcytic anemia and alopecia that spares the head (a
“mask” of fur); the phenotype results from systemic iron deﬁciency due
to impaired intestinal iron absorption secondary to inappropriately high
levels of hepcidin production for the degree of iron stores [59]—the phe-
notype “opposite” that of ARHH. The mask mutation is a splicing mu-
tation in the Tmprss6 gene, which encodes a transmembrane
serine protease that is highly and selectively expressed in the
liver [59]. Targeted disruption of Tmprss6 produces an identical
phenotype [59,60]. Erythropoietin administration to mask mice
improves the anemia and decreases hepcidin levels, suggesting
that Tmprss6 is not required for erythropoietin-dependent regula-
tion of hepcidin expression [61]. Intercrossing Tmprss6-deﬁcient
animals with Hfe-deﬁcient or liver-speciﬁc Hfe-transgenic mice
demonstrated that Hfe does not modify the hepcidin overexpres-
sion or iron deﬁciency due to inactivation of Tmprss6 [62]. In con-
trast, coexisting Bmp6 deﬁciency can correct the Tmprss6 anemia
and the Tmprss6- and Hjv-deﬁcient animal has a phenotype indis-
tinguishable from Hjv deﬁciency alone [63–65]. Taken together,
these results demonstrate that Tmprss6 acts in iron-dependent
BMP/SMAD signaling in hepatocytes, and support the idea that
Tmprss6, like Hjv, acts downstream of Hfe in regulating hepcidin
gene transcription. Furthermore, these results are compatible
with the notion, as has been demonstrated in tissue culture, that
Tmprss6 functions by proteolyzing Hjv from the hepatocyte cell
surface [66].
Recent work also suggests that Hjv function may be controlled by
factors other than Tmprss6. Similar to AR HHmodels, transgenic knock-
down of the deleted in colorectal cancer family member neogenin re-
sults in iron loading, decreased hepcidin expression and reduced BMP
signaling [67]. Intriguingly, in this animal model loss of neogenin de-
creases Hjv protein expression in both muscle and liver tissue suggest-
ing it may play a general role in maintenance of the protein on the cell
membrane. Other work also indicates that the liver-speciﬁc microRNA
miR-122 regulates expression of Hjv. Depletion ofmiR-122 by injection
of speciﬁc anti-miR reagents produced systemic iron deﬁciency in mice
alongwith increasedmRNA expression of hepcidin, Hjv andHfe; in vitro
work demonstrated thatmiR-122modulates gene expression by target-
ing the 3′ untranslated region of Hjv and Hfe mRNA [68].
1.2.4. Regulation of hepcidin by anemia and hypoxia
The regulation of hepcidin expression by anemia and hypoxia is a
complicated area of study, largely because anemia and hypoxia neces-
sarily coexist, making it difﬁcult to segregate the effect of one from
the other. Nonetheless, it does appear that liver hepcidin expression
is suppressed by a bone marrow-derived factor likely elaborated by
erythroid cells. This as yet undeﬁned factor, termed “the erythroid
regulator” of iron metabolism, appears to exert a particularly strong
effect in the setting of ineffective erythropoiesis—a condition inwhich erythropoietic mass is expanded, but reduced numbers of ma-
ture, enucleated erythrocytes are released due to death of precursors
in the bone marrow. Two such erythroid precursor-derived factors,
growth differentiation factor 15 (GDF15) and twisted gastrulation
(TWSG1), both of which inhibit BMP signaling, have been advanced
as candidates the erythroid regulator. Both are elevated in anemias
characterized by ineffective erythropoiesis and both inhibit hepcidin
expression in vitro, but in neither case have animal mutant models
validating this effect in vivo been reported [69].
As described above, hypoxia inducible factors mediate the sys-
temic and cellular response to hypoxia. The role of liver-derived
HIFs in the direct regulation of hepcidin expression has been in-
vestigated with tissue-speciﬁc mouse models of HIF deﬁciency.
Hepatocyte-speciﬁc Hif1α deletion in mice partially blunts the de-
crease in hepcidin levels observed in wild-type mice on an iron-
deﬁcient diet, suggesting that Hif1α is involved, but not solely
responsible, for downregulation of hepcidin expression under con-
ditions of iron deﬁciency [70]. Analysis of gene expression in mice
with hepatocyte-speciﬁc deﬁciencies in Vhlh, Hif1α and/or Hif2α
indicated that hepatic expression of iron metabolism-related
genes such as Dmt1 is dependent largely on Hif2 [71]. Mice with
hepatocyte Vhlh deﬁciency exhibit increased Hif levels and poly-
cythemia most likely secondary to their increased erythropoietin
levels; a low mean cell hemoglobin level, along with decreased
liver and spleen iron and ferritin levels, indicate a relative iron de-
ﬁciency [70]. They also exhibit decreased hepcidin levels, suggest-
ing that Vhlh is not essential for the regulation of hepcidin
expression by iron deﬁciency, and increased duodenal Fpn1
expression.
1.3. Cellular iron metabolism
Most of the iron in the body is dedicated to erythropoiesis. The deliv-
ery of iron to erythroid precursors is largely if notwholly dependent upon
TF. Fe2-TF binds to theubiquitously expressed cell surfacemembranepro-
tein TFR1 and the resulting complex is internalized via receptor-mediated
endocytosis. Endosomal acidiﬁcation lowers the afﬁnity of TF for Fe3+,
which can then be transported into the cytosol by DMT1 after reduction
to Fe2+ by the ferrioxidase Steap3. Within erythroid and non-erythroid
cells, iron is incorporated into heme, iron–sulfur clusters and iron-
dependent enzymes. Once red blood cells senesce or become damaged,
they are phagocytosed by macrophages in the spleen, bone marrow,
and other tissues. Iron is liberated from scavenged heme by heme oxyge-
nase 1, exported into plasma by Fpn1, oxidized by ceruloplasmin then
bound to and distributed by TF.
1.3.1. Appropriate regulation of erythroid TFR1 expression is essential for
erythropoiesis
Targeted deletion of Nme-1 and -2, encoding NdpkA and B, which are
highly similar and ubiquitously expressed proteins that catalyze phos-
phate transfer between ribo- and deoxyribonucleotides, results in mice
with reduced perinatal viability, growth retardation and anemia [72,73].
Decreased Tfr1 expression in erythroid precursors and decreased blood
cellular iron and heme levels, despite increased serum iron levels in the
mutant mice, suggest that NdpkA/B are essential for appropriate expres-
sion of erythroid Tfr1. Aberrant erythroid Tfr1 expression also results
from hematopoietic-speciﬁc deletion of the Stat5a/b locus encoding the
cytokine-regulated transcription factors Stat5A/B [74,75]. These mice
also exhibit a perinatal mortality and anemia despite increased serum
and liver iron levels. While decreased expression of anti-apoptotic pro-
teins and apoptosis in fetal liver, a dominant site of fetal erythropoiesis,
suggests that anemia results from apoptosis of erythroid precursors, ery-
throid cells from Stat5a/b-deﬁcient mice have markedly decreased Tfr1
mRNA and protein levels, but also decreased expression and mRNA-
binding activity of iron regulatory protein 2 (Irp2), a known post-
translational mediator of Tfr1 expression.
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incorporation into heme precursors and erythroid heme export
Mitochondrial iron import, an essential step in heme biosynthesis, is
mediated bymitoferrin (Slc25a37) [76].Whereas germlinemitoferrin de-
ﬁciency leads to embryonic lethality, induced deletion of mitoferrin in
adult hematopoietic tissues leads to severe anemia due to defective
erythroblast maturation [77]. Incorporation of iron into protoporphyrin
IX, the last step in heme biosynthesis, is catalyzed by ferrochelatase and
ferrochelatase-deﬁcientmice developmild hypochromic,microcytic ane-
mia and increased protoporphyrin levels without alterations in erythroid
iron, serum iron or hepcidin levels [78]. Intriguingly, the phenotype of
mice deﬁcient in the feline leukemia virus subgroup C receptor (Flvcr)
suggests that heme export is essential for erythroid precursor viability.
While total deletion of Flvcr inmice leads to embryonic lethality, multiple
congenital abnormalities and fetal erythropoiesis halted prior to hemo-
globinization [79], mice with postnatal Flvcr deﬁciency exhibit severe
hyperchromic, microcytic anemia and a block in erythroid maturation.
Bone marrow transplantation studies indicate that hematopoietic Flvcr
deﬁciency is sufﬁcient for the phenotype observed in globally deleted
mice,while in vitro experiments usingmacrophages derived frommutant
mice demonstrate a defect in heme export.
1.3.3. Red cell iron reclamation is essential for iron homeostasis
Given that a majority of total body iron is found in red cells, the
reclamation of red cell iron has a profound effect on iron homeostasis.
Central to such reclamation is heme oxygenase-1 (Hmox1) which cat-
alyzes the oxidation of heme to carbon monoxide, iron and biliverdin.
Hmox1 deﬁciency leads to increased perinatal lethality and, in adult
mice, anemia, hypoferremia and hepatic and renal iron loading [80]. Re-
centﬁndings suggest that Hmox1 haploinsufﬁciency inmice leads to re-
tention of erythroblasts in erythroblastic islands of the spleen [81] and
that Hmox1 deﬁciency leads to decreased viability of erythrophagocytic
macrophages, most likely due to heme toxicity [82].
Once iron is liberated from heme, it must be exported from phago-
cytic compartments; this step is thought to be mediated, in part, by
Nramp1, a homolog of Dmt1 expressed in the membranes of late endo-
somes and phagolysosomes in phagocytic cells. Nramp1-deﬁcient mice
demonstrate increased transferrin saturation, spleen iron levels and duo-
denal Fpn1 and Dmt1 expression and decreased liver iron and hepcidin
levels [83]. Upon treatment with the hemolytic agent phenylhydrazine,
deﬁcient mice have a profound decrease in Tf saturation and hematocrit,
followed by increased tissue iron levels, splenomegaly and reticulocytosis
relative to wild-type controls. These results, in conjunction with in vivo
studies on 59Fe-labeled damaged red cells, demonstrate that Nramp1 is
essential for efﬁcient hemoglobin iron recycling.
Once iron is efﬂuxed from phagolysosomal compartments within
reticuloendothelial macrophages, Fpn1 mediates its export out
of the cell into the plasma for redistribution by Tf. Mice with
macrophage-speciﬁc Fpn1 deletion develop iron accumulation in
liver Kupffer cells and splenic red pulp macrophages, mild anemia
and decreased serum iron levels and Tf saturation; iron dextran adminis-
tration worsens liver and spleen iron accumulation and corrects the ane-
mia, while an iron-deﬁcient diet has the opposite effect [84]. Liu et al. also
recently demonstrated that macrophagematuration is perturbed inmice
deﬁcient in heme-regulated eIF2α kinase (HRI), a factor that inhibits glo-
bin synthesis in heme-limited erythroid precursors; mutant mice display
impaired erythrophagocytosis in vitro and in vivo in conditions of chronic
hemolytic anemia[85].
1.3.4. Cellular iron homeostasis requires iron regulatory protein function
Iron regulatory proteins 1 and 2 (Irp1 and Irp2) are cytosolic RNA-
binding proteins that regulate the stability and translation of multiple
mRNAs encoding proteins required for iron transport, iron/sulfur cluster
assembly and heme biosynthesis. The essential nature of Irp activity has
been demonstrated by the early embryonic lethality of mice deﬁcient in
both Irp1 and Irp2 [86]. Using conditional mutants, Galy et al.demonstrated that mice with hepatocyte-speciﬁc Irp1 and Irp2 deletions
develop mitochondrial iron deﬁciency, impaired iron/sulfur cluster as-
sembly and heme biosynthesis and fatal liver failure [87]. The essential
role of Irps in iron homeostasis is further highlighted by the ﬁnding by
Moroishi et al. that F box and leucine-rich repeat protein 5 (Fbxl5),
shown to mediate iron-dependent degradation of Irp1 and Irp2 in vitro
[88,89], is essential for appropriate regulation of Irp2; the embryonic le-
thality and iron overload of Fbxl5-deﬁcient mice is largely rescued by
concomitant Fbxl5 and Irp2 deﬁciency, while hepatocyte-speciﬁc dele-
tion of Fbxl5 resulted in decreased Bmp6 and hepcidin signaling and
fatal acute liver toxicity when mice were fed an iron-rich diet [90].
1.4. Prospects for the future
The identiﬁcation of novel geneswith roles in ironmetabolism is a sig-
niﬁcant driving force in the ﬁeld of iron biology. However, many of the
currentmodels have not been investigated to the fullest.While common-
ly performed,measurements of iron levels in blood, serum, tissue or other
sites paint a static picture of a dynamic process;whilemore tedious to ex-
ecute, radioisotope studies provide essential information regardingmetal
inﬂux into, efﬂux from and distributionwithin a particular compartment.
While the lack of embryonic lethality in a mouse model indicates that a
particular gene is not essential for early development, a potential role
for such genes in early development is typically not addressed, nor is
the phenotype of young adult mice always compared to the phenotype
of agedmice. Furthermore, testing the effect of acute and chronic stresses
inmousemodels can also yield invaluable information regarding the tem-
poral role of a particular gene. Structure–function studies, while not as
high proﬁle as the establishment of novel mouse models, provide essen-
tial information regarding mechanism of function, although the ﬁeld of
iron metabolism has been hampered by the fact that cell lines that reca-
pitulate in vivo phenotypes are not always available. Despite these short-
comings, many of which reﬂect the challenges inherent to all research
studies and environments, we have seen in recent years tremendous ad-
vances in our understanding of iron biology. The establishment of new
murine models of aberrant iron metabolism and the study of previously
established models has been key to this greater understanding.
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